Deal Watch: Bristol, Pfizer Lead Off J.P. Morgan Week With Two Deals Apiece
Executive Summary
Despite no mega-deals (yet), the J.P. Morgan Healthcare Conference’s first day brings the usual flurry of deals, including a pair of tie-ups each for Bristol and Pfizer. BioNTech moves into cancer with Crescendo.
You may also be interested in...
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Deals Or No Deals, J.P. Morgan Sets The Tone For 2022
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
‘No Decision’ On Sandoz As Novartis Continues To Explore Options
Novartis said it had so far made “no decision” as it continues to consider numerous options for Sandoz, from retaining the business to separation, in order to maximize value for shareholders and capitalize upon the growing autonomy of its generics business.